HWAIL PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,640 KRW | +0.31% |
|
+3.47% | -25.62% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2015 | 106B 78.32M 6.54B | Sales 2016 | 112B 82.3M 6.87B | Capitalization | 110B 80.94M 6.75B |
|---|---|---|---|---|---|
| Net income 2015 | 5.45B 4.02M 336M | Net income 2016 | 6.38B 4.71M 393M | EV / Sales 2015 | 1.01 x |
| Net Debt 2015 | 20.17B 14.88M 1.24B | Net Debt 2016 | 5.05B 3.72M 311M | EV / Sales 2016 | 1.03 x |
| P/E ratio 2015 |
16
x | P/E ratio 2016 |
17.2
x | Employees | 130 |
| Yield 2015 |
2.32% | Yield 2016 |
1.85% | Free-Float | 56.28% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.31% | ||
| 1 week | +3.47% | ||
| Current month | +1.93% | ||
| 1 month | +3.40% | ||
| 3 months | -11.11% | ||
| 6 months | -20.58% | ||
| Current year | -25.62% |
1 week
1 603.00
1 820.00
1 month
1 551.001 820.00
Current year
1 550.002 265.00
1 year
1 550.002 410.00
3 years
1 550.004 930.00
5 years
1 303.335 933.33
10 years
1 303.335 933.33
| Managers | Title | Age | Since |
|---|---|---|---|
Pil-Jun Park
CEO | Chief Executive Officer | 63 | 01/79/01 |
Joong-Myung Cho
CEO | Chief Executive Officer | 75 | 01/13/01 |
Yong-Ho Jung
CTO | Chief Tech/Sci/R&D Officer | 72 | 01/10/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joong-Myung Cho
CEO | Chief Executive Officer | 75 | 01/13/01 |
Pil-Jun Park
CEO | Chief Executive Officer | 63 | 01/79/01 |
Sang-Chun Ahn
BRD | Director/Board Member | 61 | 01/13/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 1,640 | +0.31% | 159,194 |
| 02/24/02 | 1,635 | +1.62% | 2,213,049 |
| 30/24/30 | 1,609 | +0.37% | 64,595 |
| 29/24/29 | 1,603 | +1.14% | 112,187 |
End-of-day quote Korea S.E., May 03, 2024
More quotes
HWAIL PHARMACEUTICAL CO., LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical raw materials. The Company produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. It also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.62% | 78.7M | |
| +30.05% | 662B | |
| +21.96% | 546B | |
| -5.38% | 359B | |
| +16.67% | 323B | |
| +4.48% | 289B | |
| +13.68% | 234B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| +3.85% | 167B |
- Stock Market
- Equities
- A061250 Stock